Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 4/20 | 0.82 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29549519 | 0.90 | CYP2C19 (1.00) | CYP2C19TDP1LMNATSHRHDAC6 | |
| SCHEMBL28794825 | 0.90 | CYP2C19 (1.00) | CYP2C19TDP1LMNATSHRHDAC6 | |
| SCHEMBL3658948 | 0.85 | CYP2C19 (0.74) | CYP2C19TDP1LMNATSHRHDAC6 | |
| SCHEMBL4115493 | 0.83 | TDP1 (0.78) | CYP2C19TDP1LMNATSHRHDAC6 | |
| SCHEMBL3663220 | 0.80 | CYP2C19 (0.56) | CYP2C19LMNATSHRKMT2AGAA | |
| SCHEMBL10245818 | 0.74 | CYP2C19 (0.66) | CYP2C19TDP1LMNATSHRKMT2A | |
| SCHEMBL11483696 | 0.73 | CYP2C19 (0.64) | CYP2C19TDP1LMNATSHRKMT2A | |
| Mephenytoin SCHEMBL21766 | 0.72 | CYP2C19 (1.00) | CYP2C19TDP1LMNATSHRKMT2A | |
| Mephenytoin SCHEMBL21768 | 0.72 | CYP2C19 (1.00) | CYP2C19TDP1LMNATSHRKMT2A | |
| SCHEMBL14105586 | 0.72 | CNR1 (0.51) | CYP2C19TDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2212314-A1 | IMIDAZOLIDINE-2,4-DIONE (HYDANTOIN) DERIVATIVES USEFUL AS NPY Y2 RECEPTOR MODULATORS | Novartis AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009050200-A1 | IMIDAZOLIDINE-2,4-DIONE (HYDANTOIN) DERIVATIVES USEFUL AS NPY Y2 RECEPTOR MODULATORS | NOVARTIS AG (CH) | 2009-04-23 | — | — | WO | disclosed |
| US-20090099243-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099243-A1 | ORGANIC COMPOUNDS | SLCO4C1, SLCO1B1, SLCO1B3 | CYP2C19 33/4885TDP1 2107/4885LMNA 2430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.